Wall Street is positive on Outlook Therapeutics Inc (OTLK). On average, analysts give Outlook Therapeutics Inc a Strong Buy rating. The average price target is $6.75, which means analysts expect the stock to climb by 385.61% over the next twelve months.
That average ranking earns Outlook Therapeutics Inc an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Outlook Therapeutics Inc Stock Today?
Outlook Therapeutics Inc (OTLK) stock is up 4.07% while the S&P 500 is lower by -0.65% as of 9:41 AM on Wednesday, Jul 29. OTLK is higher by $0.05 from the previous closing price of $1.34 on volume of 29,333 shares. Over the past year the S&P 500 has risen 6.81% while OTLK is lower by -40.60%. OTLK lost -$1.54 per share the over the last 12 months.
